GQR’s Post

A new age of Alzheimer's - a really timely report to browse as the APDD meeting (12th Alzheimer’s & Parkinson’s Drug Development Summit) organised by Hanson Wade Group is starting in Boston tomorrow! Christopher Cook and I will be there, give us a shout if you are around too! 👉 Currently, there are around 7 million Alzheimer's patients in the US alone. By 2050, this number is projected to rise to nearly 13 million (The lifetime risk for Alzheimer's at age 45 is 1 in 5 for women and 1 in 10 for men) 👉 We have made startling advances early Alzheimer’s disease detection, when treatments are most effective. 👉 Drugs are now available that can slow the progress of the disease, having gone from the lab to pharmacy shelves, and more are in the pipeline.  https://lnkd.in/eQ5wYsXB

Groundbreaking Alzheimer's Treatment Approved Therapies like donanemab on the horizon amplify this moment of hope. Ronald Petersen, director of the Mayo Clinic's Alzheimer's Disease Research Center, emphasizes that while this is a significant first step, it's just the beginning. However, as we enter this new era, numerous unanswered questions arise. The primary benefit of Leqembi is still under scrutiny. Will this truly impact the lives of patients and their families? Will the drug's effects change over time? Another critical concern is the accessibility and practicality of treatment. Leqembi, the brand name for lecanemab, requires bi-weekly infusions as a monoclonal antibody. Will older adults in their 70s and 80s be willing and able to travel to medical centers for infusions twice a month, undergoing frequent MRI scans and physician visits to monitor for potential side effects such as brain bleeds or swelling? As families and healthcare providers tread cautiously, these questions illuminate the narrative of promise and uncertainty. Yet, one thing is clear: this milestone infuses hope and complexity into the fight against Alzheimer's disease. #AlzheimersTreatment #FDAApproval #Leqembi #MildCognitiveImpairment #HealthcareInnovation

Groundbreaking Alzheimer's Treatment Approved Therapies like donanemab on the horizon amplify this moment of hope. Ronald Petersen, director of the Mayo Clinic's Alzheimer's Disease Research Center, emphasizes that while this is a significant first step, it's just the beginning. However, as we enter this new era, numerous unanswered questions arise. The primary benefit of Leqembi is still under scrutiny. Will this truly impact the lives of patients and their families? Will the drug's effects change over time? Another critical concern is the accessibility and practicality of treatment. Leqembi, the brand name for lecanemab, requires bi-weekly infusions as a monoclonal antibody. Will older adults in their 70s and 80s be willing and able to travel to medical centers for infusions twice a month, undergoing frequent MRI scans and physician visits to monitor for potential side effects such as brain bleeds or swelling? As families and healthcare providers tread cautiously, these questions illuminate the narrative of promise and uncertainty. Yet, one thing is clear: this milestone infuses hope and complexity into the fight against Alzheimer's disease. #AlzheimersTreatment #FDAApproval #Leqembi #MildCognitiveImpairment #HealthcareInnovation

Exciting News: In a recent study published in JAMA, a medication called Donanimab has shown significant potential in reducing the progression of Alzheimer's disease. Watch the full video on youtube to learn more: https://loom.ly/Gm665Qs This breakthrough offers hope for patients and their families, as we continue the battle to end Alzheimer's. Stay informed and spread awareness. Have you come across any other promising advancements in Alzheimer's research? Share your thoughts and experiences in the comments. #AlzheimersResearch #MedicalAdvancements #HopeInTheFight

A brilliant move to take a DTC approach here. While this Alzheimer's test ($399 + $13 physician fee) is not an official diagnostic tool, this blood test will open the door for many people wanting to take more control over their health. This test measures the ratio between two types of #betaamyloid in plasma previously used in clinical trials to screen participants between Alzheimer’s disease, dementia, and mild cognitive impairment. —Beta Amyloid is one of the hallmarks of the neurodegenerative condition. Hopefully, it will spark more conversations around cognitive health. Quest Diagnostics As we see more advances in Alzheimer's therapies and drug treatments, the demand for these types of accessible tests is going to skyrocket. This is just the beginning. Thanks Conor Hale & Fierce Biotech for the coverage #Diagnostics #MedTech #Alzheimers#Dementia #knowledgeispower

⭐️ Faculty members Qian Ding and Alison Konieczny, along with Jennifer Lamberts, Tyler Bringedahl (COP '23), and Kiara Torres Garcia (COP '23) have co-authored a groundbreaking article! 📚 Title: "Association of Autoimmune Disorders and Disease-modifying Antirheumatic Drugs with the Risk of Alzheimer’s and/or Dementia: A Population Study Using Medicare Beneficiary Data" 📓 Published in Current Alzheimer Research, this research delves into the link between autoimmune disorders, disease-modifying antirheumatic drugs, and the risk of Alzheimer's and/or dementia. 🔗 Read the full article here: https://bit.ly/4br0g3Y Congratulations to the brilliant minds behind this impactful study! 🧠 #FerrisForward #FerrisPharmD #ForPharmacy

🤝 Alzheimer: Uniting for Awareness and Action 🤝   Dear colleagues and LinkedIn network,   In France, addressing Alzheimer's disease and related concerns is a pressing public health priority ⚠️, especially given the growing prevalence within our aging population 🌍   The global impact? Nearly 50 million people are affected by Alzheimer's, with 225,000 new cases reported annually in France alone 📈. And without intervention, those numbers could skyrocket to a staggering 152 million cases by 2050.   This isn't just numbers; it's about the 3 million caregivers, friends, and healthcare professionals who are on the front lines of this battle every day 💪   France has taken action with dedicated national plans, focused on improving patient care, boosting research, and providing vital family support 👨👩👧👦   Research is pushing boundaries, aiming to uncover Alzheimer's intricate mechanisms, craft game-changing treatments, and spot early-warning biomarkers 🔬   France is leading the way in groundbreaking research, aimed at refining diagnostics, treatments, and patient well-being 🏥   Count on Eurofins Optimed as your ally in the quest for clinical solutions against Alzheimer's.   Got a research project ? Connect with our sales team at 📧 optimedsales@eurofins.com 📧.   With 30+ years of experience, Eurofins Optimed is here to empower your clinical trial journey: https://lnkd.in/euxMgfCp   #Alzheimer #Eurofins #EurofinsOptimed #ClinicalResearch #ClinicalDevelopment #CRO #Biotechnology #Pharmaceuticals #worldwideday

🧠 A recent report sheds light on the evaluation methods of disease-modifying Alzheimer’s drugs by the NICE - National Institute for Health and Care Excellence. While deemed appropriate, key issues must be addressed. With breakthroughs in understanding Alzheimer's affecting 850,000 in the UK, disease-modifying dementia treatments (DMDTs) have emerged, marking a long-awaited change in Alzheimer's management. These treatments aim to alter disease progression, with drugs like lecanemab and donanemab targeting mild cognitive impairment and mild dementia, set for NICE appraisal next year. 💡The report highlights challenges such as uncertainty in defining "mild cognitive impairment" and the need for invasive tests. Additionally, the absence of long-term treatment effectiveness data and the necessity to factor in administration costs pose considerations for future evaluations. Despite challenges, NICE's methods for technology appraisal remain fitting for assessing these innovative treatments. The report follows the announcement of a £5m-funded project for Alzheimer's blood tests, bringing hope for improved diagnostics. 🅾 #marketaccess #patientaccess #alzheimersresearch #healthcareinnovation #NICE #medicaladvancements